US2021040133A1PendingUtilityA1

Food or feed composition for improving cognitive function or memory comprising extract of desalted salicornia europaea

Assignee: PHYTO CORP INCPriority: May 15, 2017Filed: Aug 26, 2020Published: Feb 11, 2021
Est. expiryMay 15, 2037(~10.8 yrs left)· nominal 20-yr term from priority
A23L 33/105A23V 2002/00C07H 15/26A61P 25/28C07H 1/06A61K 36/21A23L 33/10A61K 31/7048A61K 31/7034A23K 20/121A61K 31/34A23V 2200/322
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a pharmaceutical composition comprising an acanthoside B compound as an effective ingredient for preventing or treating dementia or for improving a cognitive function. In the present invention, a desalted glasswort extract, and acanthoside B, which is isolated from the extract and acts as an effective ingredient inhibitory of acetylcholine esterase, were found to have an excellent neuroprotective activity through the inhibition of neuroinflammation and to improve memory retention and remarkably enhance spatial cognitive ability as measured by passive avoidance test and Y-maze test in a scopolamine-induced amnesic animal model. The acanthoside B or glasswort extract of the present invention can be applied to a pharmaceutical composition for preventing or treating dementia, a pharmaceutical composition for improving a cognitive function, or a health functional food or feed for improving memory retention and cognitive function.

Claims

exact text as granted — not AI-modified
1 - 10 . (canceled) 
     
     
         11 . A method for the treatment of dementia comprising the step of:
 administering, to a subject, a composition comprising a desalted  Salicornia  spp. extract, wherein the desalted  Salicornia  spp. extract comprises acanthoside B represented by chemical formula 1 below.   
       
         
           
           
               
               
           
         
       
     
     
         12 . The method of  claim 11 , wherein the dementia is Alzheimer-type dementia, cerebrovascular dementia, neuroinflammatory dementia, dementia with Lewy bodies (DLB), multi-infarct dementia (MID), frontotemporal lobar degeneration (FTLD), Pick's disease, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), Parkinson's disease, or Huntington's disease. 
     
     
         13 . The method of  claim 11 , wherein the desalted  Salicornia  spp. extract is obtained by subjecting desalted  Salicornia  spp. to extraction using water or 50-100 (v/v) % of a C1 to C4 lower alcohol. 
     
     
         14 . The method of  claim 11 , wherein the desalted  Salicornia  spp. extract obtained by subjecting a desalted  Salicornia  spp. enzymatic hydrolysate to extraction using water or 50-100 (v/v) % of a C1 to C4 lower alcohol. 
     
     
         15 . A method for improvement or amelioration of cognitive ability or memory, comprising the step of:
 administering, to a subject, a composition comprising a desalted  Salicornia  spp. extract, wherein the desalted  Salicornia  spp. extract comprises acanthoside B represented by chemical formula 1 below.   
       
         
           
           
               
               
           
         
       
     
     
         16 . The method of  claim 15 , wherein the desalted  Salicornia  spp. extract is obtained by subjecting desalted  Salicornia  spp. to extraction using water or 50-100 (v/v) % of a C1 to C4 lower alcohol. 
     
     
         17 . The method of  claim 15 , wherein the desalted  Salicornia  spp. extract is obtained by subjecting a desalted  Salicornia  spp. enzymatic hydrolysate to extraction using water or 50-100 (v/v) % of a C1 to C4 lower alcohol.

Join the waitlist — get patent alerts

Track US2021040133A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.